The latest on the race for a COVID-19 vaccine.

As new information continues to emerge during the pandemic, it can be challenging to stay up to date with the most accurate reports and developments regarding potential COVID-19 vaccines. While we do not yet have a vaccine or treatment that has proven to work safely against the coronavirus, the industry is inching closer to groundbreaking discoveries and results as clinical trials enter their next phases.

At Praxis, we’ve continued to stay informed of the top stories, even working on some of the rapidly changing advancements happening in clinical trials. So to help break down the latest, we’ve rounded up the top stories for you take a look at:

Biotech company Moderna has begun a phase 3 vaccine trial. You can read more in this article published by the New York Times.

  • Moderna’s study, named the COVE Study, is currently enrolling 30,000 healthy volunteers at nearly 90 sites around the United States. Praxis is proud to be currently working with the biotech company on this particular study.
  • Moderna previously reported promising results from the first study of the vaccine, which enrolled a small number of people, showing it induced immune responses and was generally safe. You can find out more by checking out this article by the Wall Street Journal.

 The New York Times article also mentions that Pfizer, along with German company BioNTech, will recruit 30,000 people from Brazil, Argentina, Germany, and 39 states in the US as part of the latest stage of its coronavirus vaccine study.

 Another possible coronavirus vaccine has been co-developed by the University of Oxford and pharmaceutical company AstraZeneca. A large study for this vaccine began in May in the UK and is due to enter a phase 3 study in the US in August, according to the Wall Street Journal.

To stay updated, visit the FDA’s website for roundups regarding vaccinations, testing, and more. You can also stay up to date with relevant industry stories by following Praxis on Twitter, Facebook, and LinkedIn.

Any questions? Want to know more?

Contact us today.